share_log

424B5: Prospectus

424B5: Prospectus

424B5：募资说明书
美股SEC公告 ·  08/21 13:22
Moomoo AI 已提取核心信息
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporation, a medical technology company, has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, dated August 20, 2024. Under the agreement, SeaStar Medical may offer and sell up to $25 million of its common stock from time to time through Wainwright. The sales may be made on the Nasdaq Capital Market or other existing trading markets in the United States. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of SeaStar Medical. The offering will terminate upon the termination of the agreement by either SeaStar Medical or Wainwright. This move comes after SeaStar Medical's recent developments, including the receipt of an approvable letter from the FDA for its Selective Cytopheretic Device (SCD) for pediatric use and the initiation of a pivotal trial for the SCD in adult patients with acute kidney injury. The company's common stock and warrants are traded on Nasdaq under the symbols 'ICU' and 'ICUCW,' respectively.
SeaStar Medical Holding Corporation，一家医疗科技公司，已与H.C. Wainwright & Co.，LLC签订了一项市场及市场协议，协议日期为2024年8月20日。根据协议，SeaStar Medical可以从时间到时间通过Wainwright向市场销售高达2500万美元的普通股。这些销售可以在纳斯达克资本市场或美国其他现有交易市场上进行。Wainwright将充当销售代理，并将尽商业上的合理努力代表SeaStar Medical出售股票。该发行将在SeaStar Medical或Wainwright之一终止协议时终止。此举是基于SeaStar Medical最近的发展，包括获得FDA针对其用于小儿的选择性细胞分离装置（SCD）的可批准信函，以及在急性肾损伤成年患者中启动SCD关键试验。公司的普通股和认股权证分别在纳斯达克上以“ICU”和“ICUCW”符号交易。
SeaStar Medical Holding Corporation，一家医疗科技公司，已与H.C. Wainwright & Co.，LLC签订了一项市场及市场协议，协议日期为2024年8月20日。根据协议，SeaStar Medical可以从时间到时间通过Wainwright向市场销售高达2500万美元的普通股。这些销售可以在纳斯达克资本市场或美国其他现有交易市场上进行。Wainwright将充当销售代理，并将尽商业上的合理努力代表SeaStar Medical出售股票。该发行将在SeaStar Medical或Wainwright之一终止协议时终止。此举是基于SeaStar Medical最近的发展，包括获得FDA针对其用于小儿的选择性细胞分离装置（SCD）的可批准信函，以及在急性肾损伤成年患者中启动SCD关键试验。公司的普通股和认股权证分别在纳斯达克上以“ICU”和“ICUCW”符号交易。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息